An artificial intelligence system reads routine tumor slides to predict gene mutations in melanoma, potentially shortening the path to targeted therapy, Bioengineer.org reports.

The approach taps digitized pathology — slides dermatopathologists already prepare — to infer mutational status without waiting on separate molecular testing. For clinicians treating advanced melanoma, that distinction matters. Targeted therapies, such as BRAF and MEK inhibitor combinations, only work when the tumor carries the matching mutation.

What does the model actually do?

The system analyzes histopathology images of tumor tissue and flags patterns linked to specific gene mutations. Rather than replacing sequencing, it works as a triage tool: it can suggest which patients likely carry actionable mutations while confirmatory molecular tests run.

That ordering step is where the time savings sit. Conventional workflows send tissue for genetic panels after pathology review, adding days before an oncologist can pick a targeted regimen. A slide-based prediction could let care teams initiate the right workup, or even provisional planning, earlier.

Why mutation status drives melanoma treatment

Melanoma was among the first solid tumors where targeted therapy reshaped survival. Mutations in genes such as BRAF divide patients into those who qualify for inhibitor combinations and those who need immunotherapy or other routes.

A wrong or delayed read on mutation status delays the right drug. Any tool that infers status from images dermatology labs already produce could compress that lag.

What dermatology practices should watch

The report frames this as research-stage capability. Bioengineer.org's headline positions the AI as offering "faster targeted therapy triage," not as an approved diagnostic.

Key open questions before clinical uptake:

• Sensitivity and specificity of mutation prediction on external validation cohorts
• Which mutations the model covers, and at what prevalence in real-world slide archives
• Regulatory pathway — whether it clears as a clinical decision support tool or a diagnostic
• Integration with existing digital pathology workflows in dermatopathology labs

Digital pathology adoption remains uneven across dermatology practices, which could shape how quickly an image-based predictor reaches routine use.

The road ahead

If validated prospectively, slide-reading AI could become a standard pre-screen in melanoma care, routing tissue to the right molecular test and helping clinicians discuss targeted options with patients sooner.